Skip to content
Companies

Longeveron

Bone marrow cell therapy for heart defects and frailty

Raised to date

$15.9M

of $33.5M offered across 1 Form D filing

Still open
$17.6M
Investors
7
Last filed
Mar 25, 2026

About

Longeveron is a clinical-stage biotechnology company in Miami, Florida developing allogeneic cellular therapies for life-threatening and aging-related conditions in children and the elderly. Its lead investigational product, Lomecel-B (laromestrocel), is a bone marrow-derived medicinal signaling cell (MSC) therapy manufactured in the company's own Miami cell processing facility. Lomecel-B is in clinical development for hypoplastic left heart syndrome, pediatric dilated cardiomyopathy, Alzheimer's disease, and age-related frailty. The company trades on Nasdaq under the ticker LGVN.

A single scalable allogeneic MSC platform pursued across both rare pediatric cardiac disease and Alzheimer's, manufactured in-house, with FDA Rare Pediatric Disease and RMAT designations supporting the programs.

Funding

  • EquityFiled Mar 25, 2026Form D
    $15.9M/ $33.5M

Product

Lomecel-B (laromestrocel)

Cell therapy

An investigational allogeneic, bone marrow-derived medicinal signaling cell (MSC) therapy isolated from tissue donated by healthy adult donors and manufactured at Longeveron's Miami facility.

  • Allogeneic (donor-derived), not patient-specific
  • Manufactured in Longeveron's own Miami cell processing facility
  • In clinical trials for HLHS, pediatric dilated cardiomyopathy, Alzheimer's disease, and aging frailty

Built for

Pediatric cardiology and neurology treatment centers, and ultimately patients with hypoplastic left heart syndrome, pediatric dilated cardiomyopathy, Alzheimer's disease, and age-related frailty

People on file